Transthyretin Amyloid Cardiomyopathy (ATTR-CM) For Professionals
Eliminate the What-If. Learn When to Rule Out ATTR-CM.
When patients present with preserved ejection fraction and no clear cause, it’s time to consider Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The symptoms can be similar, but ATTR-CM has a different prognosis and requires unique management strategies.
Learn when to test and more about ATTR-CM on our podcast series.
Hear from the Experts
Michelle Kittleson, M.D., Ph.D.
- Director of Heart Failure Research and Post-Graduate Education in Heart Failure and Transplantation
- Associate Professor of Medicine at Smidt Heart Institute, Cedars-Sinai
Amrut V. Ambardekar, M.D.
- Medical Director Cardiac Transplant Program
- Associate Professor, Medicine-Cardiology University of Colorado
Richard Hawkins
ATTR-CM Survivor
ATTR-CM Expert Podcast Series
Learn when to test and even more about ATTR-CM on our podcast series.
Episode 1 - What is ATTR-CM?
Episode 2 - Causes and Symptoms of ATTR-CM
Episode 3 - Diagnosis and Treatment Options
What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. Read about the types of ATTR-CM, as well as the risk factors, symptoms, and treatment.